VitalCare Signs LOI For Diabetes Treatment Center In Utah
Posted on: Monday, 28 April 2008, 09:00 CDT
VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets:VDTI) a Nevada corporation, today announced they have signed a letter of intent to establish a joint-venture relationship with South Valley Inpulse Center, LLC, an existing Diabetes Treatment Center in Draper, Utah. The center will be administering the FDA approved iCAT treatment for Type 1 and Type 2 diabetes patients.
Jimmy McDougald, CEO, stated, "This is the part of our Mid-West launch and we are excited to be offering iCAT therapy to diabetics in this region. We see this as an opportunity to work with an established team of healthcare professionals."
Diana Harrison, Managing Partner of South Valley Inpulse Center, said, "We are excited about this opportunity to work with VitalCare to expand our program, giving more people access to this treatment and the hope in a better quality of life."
About VitalCare Diabetes Treatment Centers, Inc.
VitalCare Diabetes Treatment Centers, Inc. is a company specializing in providing Administrative, Marketing, Business Development, Strategic Planning, Clinical Oversight and Clinical Management Services to the Diabetes Healthcare Sector, with an emphasis in bringing "Cutting Edge" medical devices and healthcare services direct to consumers, focusing on an emerging FDA approved, US and European Patented technology and treatment intervention for treating Type 1 and Type 2 Diabetes known as "Intracellular Activation Therapy (iCAT)".
Safe Harbor Statement: Forward-looking statements in this release with respect to VitalCare Diabetes Treatment Centers, Inc.'s business, financial condition and results of operations, as well as matters of timing and the prospective terms of the transaction described are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward- looking statements, including, but not limited to, certain delays beyond VitalCare Diabetes Treatment Centers, Inc.'s control with respect to market acceptance of their technology and/or products, whether financing will be available, the effect of the application of acquisition accounting policies as well as certain other risk factors which are and may be detailed from time to time in VitalCare's filings with the Securities and Exchange Commission.
Source: Business Wire
Related Articles
- ONGLYZA(TM) (Saxagliptin) Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People With Type 2 Diabetes
- VitalCare to Open New Diabetes Treatment Centers in Indiana
- VitalCare Signs LOI for Diabetes Treatment Centers in Indiana
- VitalCare Offers Licenses for Diabetes Treatment Centers
- VitalCare Announces National Launch of Diabetes Treatment Centers
- VitalCare Acquires Diabetes Treatment Center in Scottsdale, Arizona
- WunderMarx Launches Web Site for UC Irvine Center for Diabetes Treatment and Research
- TolerRx Receives Orphan Drug Designation From FDA for TRX4 for the Treatment of New-Onset Type 1 Diabetes
- Diabetic Treatment Centers of America Announces Letter of Intent to Acquire Movement Disorder Technologies
User Comments (0)

RSS Feeds